Pyxis Oncology, Inc. Common Stock PYXS
i
Market datapartial · fetched 2026-11-13T18:51:50.522Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:50:32.590681203Z
FundamentalsAlpha Vantage · unavailable
Pyxis Oncology, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.47 | 798.2% | 401.5% | 1.09 | 744.1% | 54.3% |
| 25Δ | 6.79 | 753.6% | 358.1% | 1.23 | 654.6% | 45.2% |
| 30Δ | 6.12 | 709.0% | 314.8% | 1.38 | 565.1% | 36.0% |
| 35Δ | 5.44 | 664.5% | 271.4% | 1.51 | 485.1% | 27.8% |
| 40Δ | 4.76 | 619.9% | 228.1% | 1.63 | 466.7% | 25.1% |
| 45Δ | 4.08 | 575.3% | 184.8% | 1.74 | 448.3% | 22.4% |
| 50Δ | 3.40 | 530.7% | 141.4% | 1.85 | 429.9% | 19.8% |
| 55Δ | 2.72 | 486.1% | 98.1% | 1.96 | 411.5% | 17.1% |
| 60Δ | 2.05 | 441.5% | 54.7% | 2.07 | 393.1% | 14.4% |
| 65Δ | 2.18 | 374.7% | 11.8% | |||
| 70Δ | 2.29 | 356.3% | 9.1% | |||
| 75Δ | 2.40 | 337.9% | 6.4% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 7.47
- IV
- 798.2%
- B/E move
- 401.5%
- Pseudo strike
- 1.09
- IV
- 744.1%
- B/E move
- 54.3%
25Δ
- Pseudo strike
- 6.79
- IV
- 753.6%
- B/E move
- 358.1%
- Pseudo strike
- 1.23
- IV
- 654.6%
- B/E move
- 45.2%
30Δ
- Pseudo strike
- 6.12
- IV
- 709.0%
- B/E move
- 314.8%
- Pseudo strike
- 1.38
- IV
- 565.1%
- B/E move
- 36.0%
35Δ
- Pseudo strike
- 5.44
- IV
- 664.5%
- B/E move
- 271.4%
- Pseudo strike
- 1.51
- IV
- 485.1%
- B/E move
- 27.8%
40Δ
- Pseudo strike
- 4.76
- IV
- 619.9%
- B/E move
- 228.1%
- Pseudo strike
- 1.63
- IV
- 466.7%
- B/E move
- 25.1%
45Δ
- Pseudo strike
- 4.08
- IV
- 575.3%
- B/E move
- 184.8%
- Pseudo strike
- 1.74
- IV
- 448.3%
- B/E move
- 22.4%
50Δ
- Pseudo strike
- 3.40
- IV
- 530.7%
- B/E move
- 141.4%
- Pseudo strike
- 1.85
- IV
- 429.9%
- B/E move
- 19.8%
55Δ
- Pseudo strike
- 2.72
- IV
- 486.1%
- B/E move
- 98.1%
- Pseudo strike
- 1.96
- IV
- 411.5%
- B/E move
- 17.1%
60Δ
- Pseudo strike
- 2.05
- IV
- 441.5%
- B/E move
- 54.7%
- Pseudo strike
- 2.07
- IV
- 393.1%
- B/E move
- 14.4%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.18
- IV
- 374.7%
- B/E move
- 11.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.29
- IV
- 356.3%
- B/E move
- 9.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.40
- IV
- 337.9%
- B/E move
- 6.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 202.64% | |
| 189.90% | |
| 182.24% | |
| 189.27% | |
| 184.18% | |
| 178.17% | |
| 172.40% | |
| 155.43% | |
| 184.56% |
Biotechnology
QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in…
More →RANI
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the…
More →RAPP
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated…
More →RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of…
More →RCKT
Description unavailable
More →